Invivogen
Menu

InvivoGen's product citations

Citations

InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).

Citations search

You can search by ‘Product Name’ or ‘Year’.

Find a citation by product name
Enter a year of publication
Product Citation Year Journal Authors Page
R848 (Resiquimod) Inflammasome-induced extracellular vesicles harbour distinct RNA signatures a... 2021 J Extracell Vesicles Budden C.F. et al. DOI: 10.1002/jev2.12127
Alhydrogel® adjuvant 2% Development of a novel ZIKV vaccine comprised of immunodominant CD4+ and CD8+... 2021 Vaccine Sun J. et al. OI: 10.1016/j.vaccine.2021.07.036
Alhydrogel® adjuvant 2% Development of combination adjuvant for efficient T cell and antibody respons... 2021 PLoS One. Haseda Y. et al. DOI: 10.1371/journal.pone.0254628
Adju-Phos® adjuvant Development of combination adjuvant for efficient T cell and antibody respons... 2021 PLoS One. Haseda Y. et al. DOI: 10.1371/journal.pone.0254628
EIF2AK2 Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote vir... 2021 Cell Rep. Zaman A. et al. DOI: 10.1016/j.celrep.2021.109491
TLR-Related Dominant Negative Genes Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote vir... 2021 Cell Rep. Zaman A. et al. DOI: 10.1016/j.celrep.2021.109491
Poly(I:C) LMW Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote vir... 2021 Cell Rep. Zaman A. et al. DOI: 10.1016/j.celrep.2021.109491
J774-Dual™ Cells High potency STING agonists engage unique myeloid pathways to reverse pancrea... 2021 J Immunother Cancer. Ager C.R. et al. DOI: 10.1136/jitc-2021-003246
THP1-Dual™ Cells High potency STING agonists engage unique myeloid pathways to reverse pancrea... 2021 J Immunother Cancer. Ager C.R. et al. DOI: 10.1136/jitc-2021-003246
IFA Antigenic and immunogenic evaluation of permutations of soluble hepatitis C v... 2021 PLoS One. Prentoe J. et al. DOI: 10.1371/journal.pone.0255336
AddaVax™ Antigenic and immunogenic evaluation of permutations of soluble hepatitis C v... 2021 PLoS One. Prentoe J. et al. DOI: 10.1371/journal.pone.0255336
Poly(dA:dT) FIP200 restricts RNA virus infection by facilitating RIG-I activation. 2021 Commun Biol. Wang L. et al. DOI: 10.1038/s42003-021-02450-1
5'ppp-dsRNA FIP200 restricts RNA virus infection by facilitating RIG-I activation. 2021 Commun Biol. Wang L. et al. DOI: 10.1038/s42003-021-02450-1
LPS-B5 (LPS from E. coli O55:B5) FIP200 restricts RNA virus infection by facilitating RIG-I activation. 2021 Commun Biol. Wang L. et al. DOI: 10.1038/s42003-021-02450-1
Poly(A:U) FIP200 restricts RNA virus infection by facilitating RIG-I activation. 2021 Commun Biol. Wang L. et al. DOI: 10.1038/s42003-021-02450-1
Poly(I:C) HMW FIP200 restricts RNA virus infection by facilitating RIG-I activation. 2021 Commun Biol. Wang L. et al. DOI: 10.1038/s42003-021-02450-1
Poly(dG:dC) FIP200 restricts RNA virus infection by facilitating RIG-I activation. 2021 Commun Biol. Wang L. et al. DOI: 10.1038/s42003-021-02450-1
Poly(I:C) LMW FIP200 restricts RNA virus infection by facilitating RIG-I activation. 2021 Commun Biol. Wang L. et al. DOI: 10.1038/s42003-021-02450-1
ODN 1585 - TLR9 ligand Effective Cytotoxicity of Dendritic Cells against Established T Cell Lymphoma... 2021 J Immunol. Dubois S. et al. DOI: 10.4049/jimmunol.2001123
R848 (Resiquimod) Effective Cytotoxicity of Dendritic Cells against Established T Cell Lymphoma... 2021 J Immunol. Dubois S. et al. DOI: 10.4049/jimmunol.2001123

Pages

Customer Service
& Technical Support
Contact us
Shopping cart is empty